The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J06 | Immune sera and immunoglobulins | |
| 3 | J06B | Immunoglobulins | |
| 4 | J06BD | Antiviral monoclonal antibodies | |
| 5 | J06BD01 | Palivizumab |
| Active Ingredient | Description | |
|---|---|---|
| Palivizumab |
Palivizumab is a humanised IgG1Îș monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). This humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences. It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| SYNAGIS Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
